From Vienna to the world: Why Austria is a key global location for Boehringer

Austria is among the most research-intensive countries in Europe, investing around 3.35% of GDP in research and development – placing it among the EU’s leading innovation locations. In the Life Sciences sector in particular, companies benefit from excellent infrastructure, internationally networked research institutions and a strong talent pool. Vienna also stands out for its political stability, high quality of life and international appeal.

Over the past ten years, Boehringer Ingelheim has invested more than one billion euros in expanding its Vienna site. The opening of the €60 million “Angelika Amon” research building has further strengthened Vienna as a global oncology centre. At the same time, a new administrative building representing an investment of around €100 million is being built, creating additional capacity by 2027.

The Regional Center Vienna manages the business across more than 30 countries, combining global responsibility with local excellence. With annual research expenditure of €200–300 million, the company ranks among Austria’s largest private R&D investors and lends lasting strength to the Life Sciences ecosystem.

The ABA supports international companies with investment, expansion and long-term site development. It acts as the central interface with the authorities and political decision-makers and provides support throughout complex coordination processes. For companies like Boehringer Ingelheim, this support delivers planning certainty and strengthens Austria as a sustainable investment location.